English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The aim of the study was to investigate the effect of 2 nd -line pazopanib on the different CTCs subpopulations in SCLC patients and evaluate the clinical relevance of their changes. Different CTCs subpopulations were evaluated before pazopanib initiation (n = 56 patients), after one-cycle (n = 35) and on disease progression (n = 45) by CellSearch and double immunofluorescence using anti-CKs and anti-Ki67, anti-M30 or anti-Vimentin antibodies. Before treatment, CTCs were detected in 50% of patients by CellSearch whereas 53.4%, 15.5% and 74.1% patients had CK + /Ki67 + , CK + /M30 +  and CK + /Vim +  CTCs, respectively. One pazopanib cycle significantly decreased the number of CTCs as detected by CellSearch ( p  = 0.043) as well as the number of CK + /Ki67 +  ( p  < 0.001), CK + /M30 +  ( p  = 0 . 015) and CK + /Vim +  ( p  < 0 . 001) cells. On disease progression, both the incidence and CTC numbers were significantly increased (CellSearch,  p  = 0.027; CK + /Ki67 + ,  p  < 0.001; CK +/ M30 + ,  p  = 0.001 and CK + /Vim + ,  p  < 0 . 001) .  In multivariate analysis, the detection of CK + /Vim +  CTCs after one treatment cycle (HR: 7.9, 95% CI: 2.9–21.8;  p  < 0.001) and CTCs number on disease progression, as assessed by CellSearch, (HR: 2.0, 95% CI: 1.0–6.0;  p  = 0.005) were emerged as independent factors associated with decreased OS. In conclusion, pazopanib can eliminate different CTC subpopulations in patients with relapsed SCLC. The analysis of CTCs could be used as a dynamic biomarker of treatment efficacy.

scientific reports

Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib